Clinical trials: Tocilizumab, open to volunteers
Rheumatoid Arthritis
Stand UP to Rheumatoid Arthritis (SUPRA)
Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient.
- Trial name
- SUPRA (NCT05305066)
- Testing
- TNFi, Anti-IL6, JAKi
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- Marie Hudson, MD
Dermatomyositis
RCT of Tocilizumab for Anti-MDA5+DM
The goal of this clinical trial is to learn if tocilizumab works to treat anti-MDA5+ dermatomyositis (anti-MDA5+DM) in adults. It will also learn about the safety of tocilizumab.
- Trial name
- PROMIS-MDA5 (NCT07377058)
- Testing
- Tocilizumab, Standard medical treatment
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Peking Union Medical College Hospital
Calcium Pyrophosphate Deposition Disease
Tocilizumab in Chronic Inflammatory CPPD Disease
The aim of this clinical trial is to determine the efficacy of tocilizumab (an IL-6 inhibitor) in treatment-refractory chronic inflammatory forms of CPPD.
- Trial name
- TociCCAre (NCT07254637)
- Testing
- Tocilizumab
- Where
- 12 sites in France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lung Cancer, Nonsmall Cell
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
- Trial name
- NCT04691817
- Testing
- Atezolizumab, Tocilizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Multiple Myeloma, Relapsed Cancer
Plan Development for Giving Teclistamab in the Outpatient Setting
This is a pilot study to develop an outpatient-based process for the administration of teclistamab for for relapsed/refractory multiple myeloma patients and to evaluate the burden on caregivers of patients receiving outpatient…
- Conditions
- Multiple Myeloma, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT06251076
- Testing
- Teclistamab, Tocilizumab
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto
Extra Corporeal Membrane Oxygenation, Decanulated Alive
Modeling of Intracerebral Vascularization After Extracorporeal Membrane Oxygenation in Children
Extra corporeal membrane oxygenation (ECMO) is a transient supplementation technique that alleviates hemodynamic and ventilatory failure.
- Trial name
- MoVa-ECMO (NCT05237232)
- Testing
- Magnetic Resonance Angiography (MRA) additional acquisition time, Modeling cerebral vascularization
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain Diseases, Ischemic Stroke
Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis
IRIS-sICAS is a multicenter, randomized, double-blind, placebo-controlled clinical trialis a multicenter, randomized, double-blind, placebo-controlled clinical trial, to assess the safety and efficacy of tocilizumab injection in…
- Conditions
- Brain Diseases, Ischemic Stroke, Ischemia, Stroke
- Trial name
- IRIS-sICAS (NCT06447701)
- Testing
- Tocilizumab, NaCl 0.9% 100ml
- Volunteers
- 486 people
- Sponsor
- Zhujiang Hospital
Malignant Pleural Effusion, Malignant Ascites
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE).
- Trial name
- RIOT2 (NCT06016179)
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Myasthenia Gravis, Generalized
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension.
- Trial name
- tMG (NCT05067348)
- Testing
- Tocilizumab Injectable Product
- Where
- 6 sites in China
- Volunteers
- 64 people
- Sponsor
- Tang-Du Hospital
Thyroid-Associated Ophthalmopathy
A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy
Thyroid-associated ophthalmopathy (TAO) is a serious, progressive, vision-threatening autoimmune disease that can be categorized into mild, moderate, and severe stages based on severity.
- Trial name
- NCT06927375
- Testing
- Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg), Tocilizumab(400mg)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Takayasu Arteritis
A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
This study aimed to compare the efficacy and safety of a precision treatment regimen based on clinical-molecular phenotypes with a conventional treatment regimen in the treatment of patients with active Takayasu's arteritis based…
- Trial name
- NCT06498089
- Testing
- Prednisone, Methotrexate, Tocilizumab
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Shanghai Zhongshan Hospital
Aneurysm, Behcet Syndrome, Vascular Type
Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
This project aims to evaluate the efficacy and safety of the combination of glucocorticoids with tocilizumab or tofacitinib, compared to the traditional combination of glucocorticoids with cyclophosphamide in the treatment of…
- Trial name
- NCT05845723
- Testing
- tocilizumab, tofacitinib, cyclophosphamide
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Peking Union Medical College Hospital
Community-acquired Pneumonia, Influenza, COVID-19
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients…
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
Myeloma, Lymphoma
PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)
Despite the consequent use of Tocilizumab together with conventional antipyretics at early/first signs of emerging CRS, CRS (and eventually the subsequent development of ICANS) remain a major concern for patients.
- Conditions
- Myeloma, Lymphoma, Leukemia
- Trial name
- PRONTO (NCT06430736)
- Testing
- Tocilizumab before CAR-T cell infusion, Tocilizumab at emerging CRS
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Rheumatoid Arthritis, Ankylosing Spondylitis
Korean College of Rheumatology Biologics and Targeted Therapy Registry
We established a nationwide biologics and targeted synthetic DMARDs registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- KOBIO (NCT01965132)
- Testing
- Biologic or targeted synthetic DMARD
- Where
- South Korea
- Volunteers
- 10,000 people
- Sponsor
- Seoul National University Hospital
Mantle Cell Lymphoma, Mantle Cell Lymphoma Refractory
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
The goal of this clinical trial is to evaluate the safety and response of combining Pirtobrutinib and Glofitimab in patients with relapsed MCL.
- Trial name
- GOlDiLOX (NCT05833763)
- Testing
- Glofitamab, Pirtobrutinib, Obinutuzumab
- Where
- 2 sites in Australia
- Volunteers
- 42 people
- Sponsor
- Australasian Leukaemia and Lymphoma Group
Behcet's Uveitis
"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"
UVB, is the first randomized prospective, head to head study, comparing Adalimumab to Tocilizumab in sight threatening uveitis of Behçet's Disease (BD). Anti-TNFα has been used for BD uveitis for 15 years.
- Trial name
- UVB (NCT05874505)
- Testing
- Adalimumab, Tocilizumab
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Takayasu Arteritis, Tocilizumab
A Pilot Study in Severe Patients With Takayasu Arteritis.
Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe.
- Conditions
- Takayasu Arteritis, Tocilizumab, Adalimumab, Treatment
- Trial name
- NCT04300686
- Testing
- Tocilizumab, Adalimumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital